Verified peer comparison
NVO vs LLY
Novo Nordisk A/S compared with Eli Lilly and Company. This page compares both source-verified company profiles and does not introduce an unverified price target.
NVO
Novo Nordisk A/S
$189.43
- Open
- --
- High
- --
- Low
- --
- Market Cap
- --
LLY
Eli Lilly and Company
$782.10
- Open
- --
- High
- --
- Low
- --
- Market Cap
- --
Company-specific comparison
Business exposure
NVO: Pharmaceuticals
LLY: Pharmaceuticals
Upside lens
NVO: Greater diagnosis, treatment capacity and reimbursement can expand the addressable obesity population. Fill-finish and active-ingredient investments can improve supply and support broader launches. Oral and combination therapies can extend leadership across obesity, diabetes and related conditions.
LLY: obesity drug adoption and pipeline expansion
Risk lens
NVO: Rival efficacy, supply and pricing can pressure share and growth across diabetes and obesity. Payer restrictions, government negotiation and affordability concerns can reduce realized economics. Quality findings or delays in complex capacity projects could constrain supply during rapid demand growth.
LLY: supply constraints and valuation expectations
Verified sources
Financial results for the first three months of 2026Novo Nordisk A/S · earningsVerified
Novo Nordisk A/S Investor RelationsNovo Nordisk A/S · companyVerified
Fetched: 7/12/2026, 12:00:00 AM UTC
Open original sourceNovo Nordisk SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified
Lilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earningsVerified
Eli Lilly Investor RelationsEli Lilly and Company · companyVerified
Fetched: 7/11/2026, 12:00:00 AM UTC
Open original sourceForm 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filingVerified
LLY editorial research profileAlphaVue Research · editorialVerified
Fetched: 7/11/2026, 12:00:00 AM UTC